Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA

Page created by Reginald Hodges
 
CONTINUE READING
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Investor Presentation
January 2021
immunoprecise.com | NASDAQ:IPA, TSXV:IPA
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Disclosures
Disclaimer

                                                                                                                                                                                     ImmunoPrecise Antibodies - Innovation Accelerated
This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”)
securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this
presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential
investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a
professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it,
including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to
the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a
representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements
This presentation includes forward-looking statements, including future-oriented financial information (“FOFI”). Forward-looking statements can generally be identified by
the use of language such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe”, “potential” & “continue” or the negative thereof or similar variations. Forward-
looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the
Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward–looking statements
attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary
statements included in this presentation. The Company undertakes no obligation to update or revise these forward–looking statements to reflect events or circumstances
that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, & anticipated events & circumstances
may affect the ultimate financial results. Projections are inherently subject to substantial & numerous uncertainties & to a wide variety of significant business, economic &
competitive risks, & the assumptions underlying the projections may be inaccurate in any material respect, including, but not limited to, those risks set forth in the
Company’s Management Discussion & Analysis for the interim period ended October 31, 2020, a copy of which may be obtained from SEDAR.com. The purpose of FOFI
provided in this presentation is to provide prospective investors with information pertaining to the Company’s long-term business objectives. Readers are cautioned that
this information may not be appropriate for other purposes.
                                                                                                                                                                                                      2
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
> CRO Services
                                                                    > Scientifically robust
                                                                    > Cutting-edge discovery technologies
                                                                       > High throughput, deep mining of antibody
                                                                         repertoires
                                                                       > Any target class, protein family, any species
ImmunoPrecise Antibodies - Innovation Accelerated

                                                                       > Excellence in single B cell interrogation
                                                                           > 10M immune cells per run, high success rates
                                                                    > End-to-end service provider
                                                                       > “Concept to clinical lead”
                                                                       > Dramatically reduce time & risk

                                                                  > Talem Therapeutics
                                                                    > Diverse, internal pipeline, at cost
                                                                    > Partnership & out-licensing opportunities
                                                                       > Partner access to several human, transgenic
                                                                        species

                                                    The IPA       > Distinguished Covid pipeline
                                                                    > Leverages complementary strengths of each

           3
                                                    Opportunity      discovery platform
                                                                       > Uniquely designed to protect & treat against
                                                                        current & emerging variants.
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Partner of Choice
Our single-source, open-access biologics technology platform offers end-to-end solutions, empowering partners to discover
and develop biologics from concept to clinical lead.

                                                                                                                            ImmunoPrecise Antibodies - Innovation Accelerated
     Computational       Discovery       Characterization    Engineering       Production
       Analyses

  > Customized to optimize antibody diversity & support clinical success
     > Unparalleled, integrated capabilities and expertise
     > Enables selection of ideal, customized campaign
  > Extensive options for customizable deliverables
     > Eliminate need for additional vendors
  > Our scientific excellence and innovative technologies are proven combo for
    success
     > Thousands of programs completed
     > Over 500 clients worldwide
        > Includes 70% of top 20 pharma
                                                                                                                                   4
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Market Deficit
> Growing trend: increasing reliance on CROs

                                                                         ImmunoPrecise Antibodies - Innovation Accelerated
    > Improve development
    > Decrease turnaround time
    > Access expertise
> Exaggerated timelines to clinic
    > Outdated technologies, many failed attempts in discovery
> High R&D costs
    > Lack of high throughput technologies, rigorous scientific acumen
> CRO solution requires advanced, high-throughput, data-
  driven technologies and expertise

                                                                                           5
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Roadmap to Success
1984   IPA Opens

2010   B cell Select™ Launches

2016   New Business Plan Launches

                                                               ImmunoPrecise Antibodies - Innovation Accelerated
2017   OmniAb ® Preferred Provider Status

       Acquisition of UPE

2018   New Management

       Headquarters Moved to US

       Acquisition of ModiQuest

2019   DeepDisplay™ Launches

       Talem created: Internal Pipeline Established

       Abthena™ & Artemis™ Launch

       Talem OmniAb ® Access to Partners

2020   Coronavirus Programs Launch (January)

       Recent Agreements: Janssen Research &
       Development, Genmab A/S, Twist Bioscience, Mila,
       Zymeworks Inc., Radboud University Medical Center,
                                                                              6
       Eindhoven University of Technology, LiteVax BV, NRC,
       University of Victoria, National Institutes of Health
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Therapeutic Antibodies
                                                    Market Growth and Convergence
                                                    > Explosive market growth for human therapeutic antibodies
                                                      > Therapeutic market expected to grow to $300B USD by 2025
ImmunoPrecise Antibodies - Innovation Accelerated

                                                      > In vitro diagnostics market projected to reach over $133B USD by 2027

                                                    > 7 of the top 10 best-selling drugs in 2019

                                                    > Drivers of CRO growth
                                                      >   Increased reliance from industry
                                                      >   Robust biopharmaceutical funding
                                                      >   Accelerated drug approval rates
                                                      >   Growing number of antibody clinical trials
                                                      >   Increase in biopharma without internal research capabilities
                                                      >   Emphasis on vendor consolidation

                                                    > IPA at intersection of two rapidly accelerating markets

                                                    > Could market surpass projections?
                                                          > Market transformation through innovation and consolidation
           7                                              > Demand in emerging markets
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Circumventing Clinical
                                                                                                                   Dead-Ends
ImmunoPrecise Antibodies - Innovation Accelerated

                                                                                                                 > Lead selection based on affinities will likely lead to clinical dead-
                                                                                                                   ends1
                                                                                                                     > Often not discovered until clinical phases 2 and 3

                                                                                                                 > Epitope binning
                                                                                                                     > Identify therapeutically relevant epitopes early
                                                                                                                     > Decrease late-stage failure

                                                                                                                 > Scientific rigor can decrease dead-end candidates and late-stage
                                                                                                                   failures
                                                                                                                     > Increase probability of clinical success

           8

                                                    1The   Importance of Epitope Binning for Biological Drug Discovery, Brooks, Benjamin, Current Drug Discovery Technologies · November 2013
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Focused on What Matters
                                                    > Development preparation for clinical success
                                                        > Antibody diversity
ImmunoPrecise Antibodies - Innovation Accelerated

                                                             > Enhance through multiple, varied species
                                                                   > Unique target epitopes
                                                        > Must avoid limited diversity in complex therapeutic programs
                                                             > Reduced diversity, fewer shots on goal
                                                                   > Convalescent plasma
                                                                   > Transgenic animals
                                                        > Discovery capabilities that maintain broad diversity

                                                    > Optionality of species
                                                        > Capitalize on natural diversity
                                                        > Capture full diversity

              9
Investor Presentation January 2021 - immunoprecise.com |NASDAQ:IPA, TSXV:IPA
Results-Oriented
                                                    > The technologies, the expertise
ImmunoPrecise Antibodies - Innovation Accelerated

                                                    > Customize and fully align from beginning to end
                                                      > Immunogen (analysis, production, custom immunization)
                                                        > We thrive on challenging targets
                                                      > Discovery platforms
                                                      > Characterization & analytics
                                                      > Manufacturing & purification
                                                      > Optimization and engineering

                                                    > Leveling the playing field
                                                      > Meaningful, translatable programs

10
ImmunoPrecise Antibodies - Innovation Accelerated

11
                                                         Select Partners
ImmunoPrecise Antibodies - Innovation Accelerated

12
SARS-CoV-2: Know Your Enemy

                                                                                        ImmunoPrecise Antibodies - Innovation Accelerated
> Vaccines
  > Leaves key populations at risk
  > Not designed for sustainable efficacy against emerging variants

> The importance of cocktail therapies against viruses
  > Mutation and natural selection

> Scientifically-robust, efficacious & durable cocktails
  Safe : Designed to protect against mutagenic escape
      > May also allow for lower dosing
  Extensive : Emphasis on efficacy for every patient, variant, & strain of SARS-CoV-2
  Efficient : Focus on retention of efficacy over seasons
      > Ability to ‘plug & play’ for future formulations

                                                                                              13
PolyTope™ Therapy: Leveraging Our Strengths
A scientifically rigorous & comprehensive cocktail therapy approach
> Leveraged complementary strengths of multiple antibody discovery platforms

                                                                                                                                  ImmunoPrecise Antibodies - Innovation Accelerated
    > No single platform is universally “the best”
> Multiple species & multiple antibody formats to cover ”blind-spots”
    > Provides more comprehensive epitope coverage
    > Increases the chance of finding “rare” clones
> Lead clones combined into cocktails
    > Broad epitope coverage to mitigate mutational escape
> Large antibody library provides enormous possibilities for plug-&-play cocktails

                                                                                                                                    14
       For an in-depth scientific look into our Polytope ™ program, visit our website’s presentation page found under Investors
From Library to Leads
Complementary discovery platforms
> Parallel, diverse library generation, screening & in-depth characterization to                Functional Selections
  converge upon a diverse portfolio of leads                                                    >   ELISA

                                                                                                                                                 ImmunoPrecise Antibodies - Innovation Accelerated
                                                                                                >   HTRF
                                                                                                >   Octet HTX (BLI-based label-free biosensor)
                                                                                                >   Cell-based Pseudovirus neutralization

                                                                                                    Functional triage to a panel
                                                         Multiple                                      of ~160 highly divers,
                                                         immunization &                               therapeutic candidates
                                                         panning strategies

                                                                               >10,000 clones                                                      15
                                                                               screened
Functional Diversity from Sequence-Diverse Libraries

                                                                            ImmunoPrecise Antibodies - Innovation Accelerated
 > Stitched full VH & VL (except llama, which are VH only)
 > Functional selections used to triage to a panel of diverse therapeutic
   leads, along with high quality reagents & diagnostic tools

                                                                                16
Higher-Order Cocktails for Robust Protection

 ˃ Identification of synergistic cocktails
 ˃ Multiple two-antibody synergistic combinations were identified
 ˃ 3- & 4-antibody combinations of synergistic pairs showed potent

                                                                     ImmunoPrecise Antibodies - Innovation Accelerated
   neutralization at low concentrations
 ˃ Our lead 4-Ab cocktail is in pre-clinical evaluation

           Different 3-Ab cocktails showing synergistic effects

                                                                           17
YoY Financials
                                                                                                                     $14,057,927
ImmunoPrecise Antibodies - Innovation Accelerated

                                                                                             $10,926,268

                                                                                                                                             $8,519,522
                                                                                                                          $8,033,984
                                                                                                                                                                     Revenue
                                                                                                                                                                     Gross Profit
                                                                     $5,441,349                   $5,294,634                                     $5,198,995
                                                                                                                                                                     Adjusted EBITDA

                                                    $2,630,515           $2,451,026
                                                                                                                                                       $1,727,875
                                                        $1,420,809

                                                                                                                                   $52,311

                                                           FY17             FY18                     FY19                    FY20            FY21 (First 6 months)

                                                                              ($3,097,483)            ($2,849,474)

 18
Cash on Hand
ImmunoPrecise Antibodies - Innovation Accelerated

                                                     $20,000,000

                                                                                                                           $16,840,908

                                                     $15,000,000

                                                     $10,000,000
                                                                                                                                               Cash On Hand

                                                                                             $5,471,650
                                                      $5,000,000

                                                                   $2,578,445                             $2,605,706
                                                                                $1,806,133

                                                             $0
                                                                     FY17         FY18         FY19         FY20       FY21 (First 6 months)

 19
Recent Company Highlights
                                                    > Partnered on Launch of SARS-CoV-2 Nanomedicine Therapy Program: December 30, 2020 IPA announced joining the COVABELP consortium, who received
                                                    EUREKA program funding through Health Holland, to develop a SARS-CoV-2-specific therapeutic nanomedicine that is administered via nasal inhalation and is also
                                                    intended for vaccination and in vitro diagnostics.

                                                    > Announced the Commencement of Trading on Nasdaq Stock Exchange: December 23, 2020 – IPA announced that its common shares had been approved
                                                    for listing on the NASDAQ Global Market under the trading ticker symbol “IPA.” Trading on the Nasdaq was expected to commence at market open on December
                                                    30, 2020.
ImmunoPrecise Antibodies - Innovation Accelerated

                                                    > Selected Lead Formulation for Preclinical PolyTope™ Antibody Cocktail Therapy: In November 2020, IPA announced the nomination the first anti-SARS-
                                                    CoV-2 cocktail therapy consisting of four, human, synergistic antibodies for preclinical testing in the well-defined, SARS-CoV-2, Syrian hamster model.

                                                    > Entered into Technology Partnership with Genmab: In November 2020, IPA entered into a research agreement with Genmab A/S, to generate novel bispecific
                                                    antibody combinations using Genmab's proprietary DuoBody® platform and IPA's proprietary antibodies in the field of infectious disease.

                                                    > Announced Strategic AI Partnership with Mila: In November 2020, IPA announced a partnership with Mila, a world-renowned artificial intelligence (AI) research
                                                    institute.

                                                    > Announced Collaboration with Twist Biosciences for the Creation of Novel, Therapeutic Antibody Products: In October 2020, IPA announced a
                                                    collaboration with Twist Biosciences to leverage Twist's silicon DNA platform to enhance its antibody therapeutics and expand its early-stage pipeline.

                                                    > Initiated Preclinical Trials for SARS-CoV-2 Vaccines in Collaboration with LiteVax: In September 2020, IPA, in partnership with LiteVax, initiated preclinical
                                                    trials for a set of vaccine candidates against SARS-CoV-2. The formulations were designed using IPA's extensive data sources and LiteVax's novel adjuvant.

                                                    > Released Second-Generation B Cell Select™: In September 2020, IPA Europe announced the release of a second-generation B-Cell platform with technology
                                                    aimed at accelerating antibody identification and discovery by increasing automation of their selection technology and subsequent single cell cloning.

                                                    > Announced Multi-Specific Antibody Collaboration with Zymeworks: In September 2020, IPA announced a research collaboration with Zymeworks to utilize
                                                    their Azymetric™ and EFECT™ platforms for the development of antibody candidates against COVID-19.

                                                    > Completed Application Process to Dual Listing on NASDAQ: In September 2020, IPA announced its application to list on the NASDAQ Global Market
                                                    ("Nasdaq") exchange and started trading December 30, 2020 under the trading ticker symbol "IPA". NASDAQ is the world's pre-eminent exchange for biotech and
                                                    pharma companies and will expand the Company's exposure and access to U.S. and international investors.
  20
Opportunities
                                                    for Growth
                                                    >Alliances and partnerships
ImmunoPrecise Antibodies - Innovation Accelerated

                                                    >Pre-clinical and clinical manufacturing
                                                    >Pre-clinical services
                                                    >Next generation technologies
                                                    >Growth of Talem Pipeline
                                                      > Genmab and Zymeworks programs
                                                      > Out-licensing deals
                                                      > Continued, aggressive asset generation

    21
Contact Information
ImmunoPrecise Antibodies Ltd.         Jennifer L. Bath, Ph.D.
Vancouver Island Technology Park      CEO & President
Unit 3204-4464 Markham Street         www.immunoprecise.com
Victoria, British Columbia,
V8Z 7X8, Canada
                                      Frédéric Chabot
                                      Investor Relations
                                      frederick@contactfinancial.com
                                      438-863-7071

                                   NASDAQ: IPA, TSX.V: IPA
Learn more about
Talem by visiting
www.talemtherapeutics.com
You can also read